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Background: Detecting impaired glomerular filtration rate (GFR) is important in intensive care units (ICU) in order
to diagnose acute kidney injuries and adjust the dose of renally excreted drugs. Whether serum Cystatin C (SCysC)
may better reflect glomerular filtration rate than serum creatinine (SCr) in the context of intensive care medicine is
uncertain.
Methods: We compared the performance of SCysC and SCr as biomarkers of GFR in 47 critically ill patients (median
SOFA (Sepsis-related Organ Failure Assessment) score of 5) for whom GFR was measured by a reference method
(urinary clearance of iohexol).
Results: Mean Iohexol clearance averaged 96 ± 54 mL/min and was under 60 mL/min in 28% of patients. Mean SCr
and SCysC concentrations were 0.70 ± 0.33 mg/dL and 1.26 ± 0.61 mg/L, respectively. Area under the ROC curve for
a GFR threshold of 60 mL/min was 0.799 and 0.942 for SCr and SCysC, respectively (p = 0.014).
Conclusions: We conclude that ScysC significantly outperfoms SCr for the detection of an impaired GFR in critically
ill patients.
Trial registration: ClinicalTrials.gov: B7072006347
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Detecting impaired glomerular filtration rate (GFR) is
important in intensive care units (ICU) in order to (i)
diagnose acute kidney injuries, (ii) prevent further deg-
radation of renal function and (iii) adjust the dose of
several renally excreted drugs. GFR estimation is usually
based on serum creatinine (SCr) which is known to be a
rather insensitive GFR biomarker. First, SCr is unable to
reflect rapidly changing GFR, i.e. in a non steady state
[1]. Moreover, SCr is not exclusively cleared by glomeru-
lar filtration but is also partially secreted by renal tu-
bules. This well-known phenomenon may account for
substantial GFR overestimation. Even more concerning* Correspondence: pierre_delanaye@yahoo.fr
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reproduction in any medium, provided the orin the context of ICU is the dependency of SCr to mus-
cular mass [2]. Critically ill patients are particularly
prone to alteration in their muscle mass not only occur-
ring during their stay in the ICU but also frequently
already present at their admission to the ICU.
As compared to SCr, serum cystatin C (SCysC) is less
dependent to muscle mass and is deemed as a more ac-
curate GFR biomarker in different situations [3,4]. Sev-
eral studies performed in critically ill patients have
suggested the superiority of SCysC for the detection of a
decreased GFR [5-9]. None of those studies has however
compared the performance of SCysC against a reference
method of GFR measurement. The real advantage of
SCysC over SCr to estimate the so-called “true” GFR still
remains to be demonstrated in the specific context of
ICU.al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tients hospitalized in ICU by measuring their urinary
clearance of iohexol [10]. The corresponding measured
value was used as a gold standard to compare the rela-
tive performance of SCr and SCysC as GFR biomarkers
in critically ill patients to detect decreased GFR. In this
specific population, several studies have suggested that
equations based on SCr are both inaccurate and impre-
cise [11-13]. We also study the ability of SCr-, ScysC-
based and combined equations to estimate GFR in these
ICU patients [14].
Methods
Subjects
Patients from 3 University hospitals (CHU Sart Tilman,
University of Liège, Liège, Belgium; Hôpital Nord, Uni-
versity Jean Monnet, Saint Etienne, France and Univer-
sity of Clermont-Ferrand, Clermont-Ferrand, France),
were included if they were older than 18 years, hemo-
dynamically stable (mean arterial blood pressure ≥
65 mmHg with no modification in vaso-active drugs
within the last 12 hours), under mechanical ventilation,
with a urinary catheter, with a minimal diuresis of
400 mL in the last 6 hours, and with SCr < 133 μmol/L
(1.5 mg/dL). This value is arbitrary and recomended by
the international guidelines of the K-DIGO (for “Kidney
Disease: Improving Global Outcomes”). The main ob-
jective was to study the performance of SCr (and new
biomarkers) to detect GFR below 60 mL/min. The sensi-
tivity of SCr is clearly insufficient but its specificity is
good. Therefore, we designed a study to try and addressTable 1 GFR estimates (SCr serum creatinine, SCysC serum cy
Basis of equation and sex SCr and SCysC values
MDRD
CKD-EPI SCr
Female SCr ≤ 0.7 mg/dL
SCr > 0.7 mg/dL
Male SCr ≤ 0.9 mg/dL
SCr > 0.9 mg/dL
CKD-EPI SCysC SCysC≤ 0.8 mg/L
SCysC >0.8 mg/L
CKD-EPI combined
Female SCr ≤ 0.7 mg/dL and SCysC≤ 0.8
SCr ≤ 0.7 mg/dL and SCysC > 0.8
SCr > 0.7 mg/dL and SCysC≤ 0.8
SCr >0.7 mg/dL and SCysC≥ 0.8
Male SCr ≤0.9 mg/dL and SCysC≤ 0.8
SCr ≤ 0.9 mg/dL and SCysC > 0.8
SCr >0.9 mg/dL and SCysC≤ 0.8
SCr >0.9 mg/dL and SCysC > 0.8clinically relevant questions. In clinical practice and in
the context of the detection of decreased GFR, there is
few doubt that a given patient with SCr above 1.5 mg/dL
suffered from kidney disease. Patients were not included
in case of liver dysfunction (prothrombin time < 50%),
pregnancy, history of allergic reaction to iodine, active
dysthyroidism and necessity of anti-inflammatory treat-
ment by steroids. This study was approved by the Ethics
Committee of CHU Sart Tilman (Liège, Belgium) and
Hôpital Nord (Saint-Etienne, France). The Belgian num-
ber of this study is BE7072006347. The French number
is 2009-010710-29. The necessary written informed con-
sent was obtained for all patients involved in the study,
including consent to publish.
GFR measurement and biomarkers
GFR was determined by urinary clearance of iohexol
(Omnipaque 240 mgI/mL, Amersham Health, New
Jersey, USA). Two hours after the injection of 10 millili-
ters of iohexol, 4 clearances periods of one hour each
were performed with plasma samples drawn at the be-
ginning and the end of each period. Urine was separately
collected for each period. Clearances periods for which
the result was outside ± 20% of the mean clearance, or
for which urine outflow was lower than 20 milliliters
were not retained for the analysis. Iohexol clearance was
determined as the mean of the different clearances pe-
riods. Iohexol samples were assayed by high perform-
ance liquid chromatography with high analytical
performances [15]. External quality control was provided
by Equalis (Uppsala, Sweden).statine C)
Equation for estimating GFR
175 × Scr-1.154 × age-0.203 × [0.742 if female]
144 × (Scr/0.7)-0.329 × 0.993age
144 × (Scr/0.7)-1.209 × 0.993age
141 × (Scr/0.9)-0.411 × 0.993age
141 × (Scr/0.9)-1.209 × 0.993age
133 × (SCysC/0,8)-0.499 × 0.996age [×0.932 if female]
133 × (Scys/0,8)-1.328 × 0.996age [×0.932 if female]
mg/L 130 × (Scr/0.7)-0.248 × (SCysC/0.8)-0.375 × 0.995age
mg/L 130 × (Scr/0.7)-0.248 × (SCysC/0.8)-0.711 × 0.995age
mg/L 130 × (SCr/0.7)-0.601 × (SCysC/0.8)-0.375 × 0.995age
mg/L 130 × (SCr/0.7)-0.601 × (SCysC/0.8)-0.711 × 0.995age
mg/L 135 × (SCr/0.9)-0.207 × (SCysC/0.8)-0.375 × 0.995age
mg/L 135 × (SCr/0.9)-0.207 × (SCysC/0.8)-0.711 × 0.995age
mg/L 135 × (SCr/0.9)-0.601 × (SCysC/0.8)-0.375 × 0.995age
mg/L 135 × (SCr/0.7)-0.601 × (SCysC/0.8)-0.711 × 0.995age
Table 2 Clinical and biological characteristics of the
population
Age (years) 62 ± 17
Gender 25 women/ 22 men
Weight (kg) 81 ± 24
Height (cm) 168 ± 10
Body mass index (kg/m2) 29 ± 8
Cause of admission Sepsis (39%)
Neurologic diseases
(32%)
Trauma (16%)
Myocardial infarction
(5%)
Other (8%)
SOFA (Sepsis-related Organ Failure Assessment)
score
5 [4;9]
GFR (mL/min) 96 ± 54
Serum creatinine (mg/dL) 0.70 ± 0.33
Serum cystatin C (mg/L) 1.26 ± 0.61
0
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Figure 1 Correlations between the inverse of creatinine and GFR (upp
GFR (lower) (y = 0,4939 + 0,004871×).
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http://www.biomedcentral.com/1471-2369/15/9SCr was measured by the IDMS traceable enzymatic
method (Roche Diagnostics, Mannheim, Germany) on
Modular apparatus. SCysC was measured by a particle-
enhanced nephelometric immunoassay on the BNII
nephelometer (Siemens Healthcare Diagnostics, Mar-
burg, Germany). The assay was calibrated against the
international certified reference material ERM-DA471/
IFCC for cystatin C. Both SCr and SCysC were sampled
at the beginning of the first clearance period, kept at
−80°C to be centrally processed at the University of
Liège (Department of Clinical Chemistry, ISO 15189
Standard-accredited laboratory).
We studied the performance of the most widely used
SCr- and ScysC-based equations, i.e. the Modification of
Diet in Renal Disease (MDRD) [16] and the CKD-
Epidemiology Collaboration (CKD-EPI) equations
(Table 1) [14].
Statistics
Data were expressed as mean ± standard deviation (SD)
when distribution was normal and as median and150 200 250 300
150 200 250 300
ol) (mL/min)
ol) (mL/min)
er) (y = 0,09024 + 0,0009156×) and the inverse of cystatin C and
Figure 2 ROC curves analysis for cystatin C (―) (AUC = 0.942)
and creatinine (——) (AUC = 0.799) to detect GFR under
60 mL/min (p = 0.014).
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http://www.biomedcentral.com/1471-2369/15/9interquartile range [IQR] if not. Performance of SCr and
SCysC was evaluated by analyzing their respective correl-
ation with iohexol clearance and by calculating the area
under the ROC curves to detect an iohexol clearance below
60 mL/min. Statistics were performed using MedCalc®
(MedCalc Software, Mariakerke, Belgium). The predictive
performance of the GFR estimates was assessed with the
following parameters:
– Absolute bias, defined as the mean difference
between estimating GFR (eGFR) and measured GFR
(mGFR), a negative value meaning that eGFR under-
estimates true GFR.
– Precision, evaluated by the standard deviation of the
mean difference between eGFR and mGFR
– Accuracy, defined as the proportion of eGFR values
within +/− 30% of the mGFR.Tabl
GFR
MDRD
CKD-E
CKD-E
CKD-E
*: p <Comparison of precision and accuracy were
performed using F-test and McNemar paired test.
A p value < 0.05 was considered as statistically
significant.Results
Fifty-one patients were included. All patients were
Caucasian. Four patients were retrospectively excluded due
to technical errors in the clearance procedure. According to
our criteria, 86% of clearance periods have been considered.
Mean GFR value in our population was 98 ± 56 mL/min.e 3 Predictive performances of the MDRD, CKD-EPI SCr, C
estimates Bias (mL/min)
+35
PI + 1
PI Scyst −26
PI combined −12
0.05 versus MDRD study equation.Characteristics of the 47 patients retained for the analysis
are presented in Table 2. While mean SCr was low (0.7 ±
0.33 mg/dL), 28% of patients had an iohexol clearance below
60 mL/min/1.73 m2. The reciprocal of SCysC better corre-
lated to iohexol clearance than the reciprocal of SCr
(r = 0.667 and r = 0.499, respectively) (Figure 1). This differ-
ence did not reach the statistical significance. SCysC was
however significantly superior to SCr to discriminate pa-
tients with an iohexol clearance above or below the thresh-
old of 60 mL/min (AUC ROC of 0.942 and 0.799,
respectively, p = 0.014) (Figure 2).
The global performances of estimating GFR were very
poor (Table 3). The best accuracy within 30% was ob-
served both for the CKD EPI SCr and combined equa-
tions (59 and 62%, respectivelly). Performance of the
MDRD was significantly worse (40%).
Discussion
SCysC is recognized to be far less influenced by muscular
mass than SCr [4]. Not surprinsingly, SCysC has been vali-
dated as a superior GFR biomarker to detect chronic kid-
ney disease (defined as GFR below 60 mL/min/1.73 m2) in
several specific populations with decreased or abnormal
muscular mass like in the elderly, cirrhotic patients, renal
transplant patients, and patients suffering from anorexia
nervosa [3,13,17]. Herein, we extend this notion to critically
ill patients. Numerous previous studies performed in se-
verely ill patients (not necessarily hospitalized in ICU) have
suggested the better performance of SCysC for detecting
AKI [5,6]. However since most of those studies did not pro-
vide a reference GFR measurement against which SCr and
SCysC could be thoroughly compared, the real added value
of SCysC as a marker of GFR has remained partly specula-
tive [6]. Among all these studies, only two of them realized
after cardiac surgery have measured GFR by a reference
method (iohexol or 51Cr-EDTA) and showed superior per-
formance of cystatin C [18,19]. Focusing specifically on crit-
ically ill patients, Le Bricon et al. measured GFR by a
reference method (51Cr-EDTA) and showed a better correl-
ation between 1/cystatin C and GFR than between 1/cre-
atinine and GFR (r = 0.755 versus r = 0.686). The authors
also demonstrated a better sensitivity-specificity of cystatin
C to detect impaired GFR [20]. However, the number of pa-
tients included in this study was very limited (n = 15). In
addition, in this study, the 51Cr-EDTA clearance wasKD-EPI SCysC, and combined equations in ICU patients
Absolute Precision mL/min Accuracy 30%
70 40
37 60*
36 53
35 62
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http://www.biomedcentral.com/1471-2369/15/9carried out according to a plasmatic method which is not
necessarily as accurate as the urinary method especially in
patients with variable and unpredictable volumes of distri-
bution [21].
As compared to the aforementioned studies, the
major strength of ours is the use of a very rigorous
method of GFR measurement in a selected population
of stable but critically ill patients. In this regard, our
results do really reflect the physiological performances
of the two biomarkers against the “true” GFR, a par-
ameter that is particularly uneasy to approach in the
context of ICU. Thus, our data strongly suggest the
superiority of SCysC over SCr in critically ill patients.
However, even if ScysC is better than SCr to detect
decreased GFR, the accuracy, and especially the preci-
sion, of ScysC-based or combined equations to esti-
mate GFR is clearly insufficient and have no added
value compared to SCr-based equations. This result is
explained by the different characteristics of the sub-
ject compared to the populations analyzed in the
CKD-EPI cohort (chronic versus acute disease, de-
creased muscular mass etc).
There are however several limitations to our study. First,
we enrolled prevalent patients and our study is purely
cross-sectional. Although patients with relatively low SCr
have been included in our study, we cannot exclude the hy-
pothesis that patient with pre-existing chronic kidney dis-
ease, have been included. Second, our sample remains
relatively limited and only includes patients with SCr <
133 μmol/L (1.5 mg/dL). Our results must be confirmed in
a larger cohort and in patients with a larger range of SCr
and GFR. Lastly, cystatin C concentration is also influenced
by non-GFR factors. While we took into account some
confounding factors (steroids and dysthyroidism), others
factors may have played a role [22,23]. Finally, the better
performance of ScysC could potentially be due to a quicker
reach of its steady state when GFR rapidly changes. How-
ever, this point remains purely speculative and cannot be
addressed in our cross- sectional designed study.
Conclusion
In conclusion, SCysC performs significantly better
than SCr in order to detect critically ill patients with
measured GFR below 60 ml/min. More generally, we
believe that SCysC is a more valid GFR biomarker
than SCr in ICU and as such, might be evaluated as
part of the AKI definition/classification in replace-
ment of SCr.
Key messages
– High percentage of patients hospitalized in intensive
care units has normal creatinine concentration but
decreased glomerular filtration rate.– Cystatin C is better than creatinine to detect
measured glomerular filtration rate less than 60 mL/
min/1.73 m2.
– All estimating equations lack of precision to
estimate GFR.
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